sur NICOX (EPA:COX)
Nicox launches FAQ page for shareholders
On August 26, 2025, Nicox SA, an ophthalmology company, announced the addition of a "Questions and Answers" page to its website. This page aims to answer shareholders' frequently asked questions about the company and its activities. Investors can also send their questions by email.
Nicox, listed on Euronext Growth Paris, develops innovative solutions for eye health. Its flagship program, NCX 470, is an eye drop designed to reduce intraocular pressure in patients with glaucoma. Other projects, such as NCX 1728 in collaboration with Glaukos, are underway.
The online presence of this new section facilitates access to information for shareholders and illustrates Nicox's commitment to transparency. Interested parties can consult the dedicated page for more details.
R. H.
Copyright © 2025 FinanzWire, tous droits de reproduction et de représentation réservés.
Clause de non responsabilité : bien que puisées aux meilleures sources, les informations et analyses diffusées par FinanzWire sont fournies à titre indicatif et ne constituent en aucune manière une incitation à prendre position sur les marchés financiers.
Cliquez ici pour consulter le communiqué de presse ayant servi de base à la rédaction de cette brève
Voir toutes les actualités de NICOX